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1. ABSTRACT 1 
 2 
Bovine group A rotavirus (RVA) is considered the major cause of diarrhea in intensively 3 
reared neonatal calves. Chicken egg yolk antibodies (IgY) are efficient in protecting 4 
neonatal calves from RVA diarrhea; however, it is unclear the value of this intervention 5 
in calves once diarrhea has appeared. The aim of the present study was to evaluate the 6 
application of RVA-specific IgY as a passive treatment in those cases. The experimental 7 
groups were: G1= RVA-specific IgY treatment; G2= no Ab treatment; and G3= 8 
colostrum deprived + no Ab treatment. IgY treatment significantly reduced virus 9 
shedding, diarrhea duration and severity compared to G2 and G3 calves. However, it 10 
caused a partial suppression of systemic Ab responses to RVA that could be associated 11 
with less severe diarrhea. The oral treatment with IgY for 7 days was associated with 12 
significantly higher antibody secreting cell responses in the calves compared with the 13 
other groups of animals.  14 
 15 
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2. INTRODUCTION 1 
 2 
Numerous epidemiologic studies have shown that group A rotaviruses (RVA) are the 3 
most frequent cause of severe gastroenteritis in young children and animals (Estes and 4 
Kapikian, 2007; Dhama et al., 2009; Martella et al., 2010). In 1969, electron microcopy 5 
was used to detect virus associated with neonatal calf diarrhea (Mebus et al., 1969). 6 
Multiple etiological agents are responsible for neonatal diarrhea in calves including RVA, 7 
Coronavirus, Escherichia coli, Salmonella species, Clostridium perfringens, 8 
Cryptosporidium and Coccidia (Bellinzoni et al., 1990; Holland, 1990; Bendali et al., 9 
1999a; Svennerholm and Steele, 2004). Among these agents, bovine RVA is 10 
considered the major cause of enteritis and diarrhea in artificially reared calves, causing 11 
important economic losses related to death, treatment costs and reduction in weight 12 
gain of affected animals (Malik et al., 1995; Martella et al., 2010). Diarrheal disease 13 
severity is enhanced by several factors including herd management, environment and 14 
host nutritional and immunological status (Saif and Smith, 1985; Bendali et al., 1999b). 15 
The disease usually occurs in 2- to 8-week-old calves and the severity decreases as the 16 
age increases. The incubation period is very short (12-24 hours) and the diarrhea is self-17 
limiting within 5 to 7 days, unless secondary bacterial infections occur (Svennerholm 18 
and Steele, 2004; Dhama et al., 2009). Bovine RVA strains are genetically and 19 
antigenically heterogeneous. Their genetic classification is based on the genes coding 20 
the two outer capsid proteins, VP7 and VP4, determining G and P types, respectively. 21 
The single most prevalent genotype combination among bovine RVA strains has been 22 
G6P[5], although spatiotemporal and herd farm type (cattle or dairy) differences in RVA 23 
















al., 2012; Papp et al., 2013). 1 
Bovine RVA is ubiquitous and infects the enterocytes of the tip of the villi within the 2 
small intestine of neonatal calves. By multifactorial mechanisms, the infection disrupts 3 
the efficiency of the absorptive enterocytes and potentially activates the enteric nervous 4 
system, inducing a malabsorptive and secretory diarrhea (Bridger, 1994; Malik et al., 5 
1995; Lundgren and Svensson, 2001; Dhama et al., 2009; Martella et al., 2010). The 6 
virus replicates quickly, generating high yields of virions and completing the 7 
transmission cycle before the host immune mechanisms can intervene (Estes and 8 
Kapikian, 2007). The affected calves manifest severe diarrhea, dehydration, 9 
hyperthermia, anorexia and lethargy (Bellinzoni et al., 1990; Holland, 1990; Bendali et 10 
al., 1999b; Dhama et al., 2009). 11 
Good management and hygienic practices can help to reduce the severity of RVA 12 
diarrhea in farm animals, while antibiotics can be used to control secondary bacterial 13 
infections and fluid and electrolyte therapy can help to restore the fluid reserves, 14 
minimizing calf mortality (Holland, 1990; Svennerholm and Steele, 2004). Being a 15 
gastrointestinal pathogen, the local gut-associated lymphoid tissue (GALT) responses 16 
are critical for virus clearance and prevention of RVA reinfection. The RVA-specific 17 
passive maternal antibodies (Ab) acquired by colostrum intake (systemically absorbed 18 
and re-secreted to the gut) as well as Ab present in maternal milk (acting locally) are key 19 
factors in protecting the neonates (Stott and Fellah, 1983; Besser et al., 1988; Saif and 20 
Fernandez, 1996; Barrandeguy et al., 1998; Fernandez et al., 1998; Hodgins et al., 21 
1999; Kohara and Tsunemitsu, 2000; Parreño et al., 2004). Dams are immunized with 22 
RVA-inactivated vaccines in the last third of pregnancy, between 60 to 30 days prior to 23 
















IgG1 immunoglobulins in colostrum (Holland, 1990; Saif and Fernandez, 1996; 1 
Barrandeguy et al., 1998; Svennerholm and Steele, 2004). Although Ab present in 2 
colostrum enter the circulation, the protection against this enteric disease is primarily 3 
dependent on the presence of RVA-specific Ab in the calves’ intestinal lumen, indicating 4 
that protection could be achieved by the presence of passive Ab in the gut lumen 5 
combined with a rapid active antibody secreting cell (ASC) response in the intestinal 6 
lamina propria (Saif and Fernandez, 1996; Fernandez et al., 1998). Regarding passive 7 
immune protection, calves receiving pooled colostrum from vaccinated dams prior to gut 8 
closure (within 4 hours after birth) were protected against severe diarrhea (Fernandez et 9 
al., 1998; Parreño et al., 2004). However, RVA-specific Ab from colostrum decline after 10 
calving and seem to be insufficient against high challenge doses of virus (Parreño et al., 11 
2004). On the other hand, supplementation of the milk diet with immune colostrum 12 
significantly reduced diarrhea and delayed viral shedding onset (Kohara and 13 
Tsunemitsu, 2000; Parreño et al., 2010). However, the production of immune milks 14 
based on colostrum supplementation was not an industrially scalable alternative. This 15 
highlights the need of another source of large amounts of Ab for immunotherapeutic 16 
purposes in a cost-efficient way.  17 
Recently, chickens have attracted considerable attention as an alternative source of 18 
antibodies, as IgY is deposited in the egg yolk in large quantities, making chickens an 19 
ideal source for specific polyclonal antibodies (Touchette et al., 2003; Kovacs-Nolan and 20 
Mine, 2004). There are several reports of chicken egg yolk Ab (IgY) being highly 21 
effective in protecting neonatal calves from bovine RVA diarrhea (Ikemori et al., 1992, 22 
1997; Kuroki et al., 1994, 1997). Our group has described that prophylactic provision of 23 
















days of life significantly reduced the severity of diarrhea after oral inoculation with 1 
virulent bovine RVA. The treatment also prevented RVA diarrhea and virus shedding 2 
after a second virus challenge (seven days after the end of the passive Ab treatment). 3 
We observed that egg yolk treatment promoted a modulatory effect on ASC responses 4 
in the gut, inducing high numbers of bovine RVA-specific IgA ASCs (Vega et al., 2011). 5 
This 14-day-long prophylactic treatment could be advantageous in dairy herds where 6 
bovine RVA is a major epidemiological concern. Still, other oral IgY-based treatments 7 
can be useful in dairy farms where RVA-associated diarrhea is a concern but less 8 
severe, decreasing the therapy´s costs. Little is known about the usefulness of IgY Ab 9 
as a treatment to bovine RVA once virus infection has already induced diarrhea under 10 
controlled environmental conditions. The aim of the present study was to determine the 11 
potential application of spray dried egg yolk powder enriched in bovine RVA-specific IgY 12 
Ab as a passive therapeutic treatment to be applied for 7 days after the appearance of 13 
diarrhea in neonatal calves experimentally challenged with virulent bovine RVA (G6P[5] 14 
strain). The potential of the powder as a commercial product was further evaluated.    15 
 16 
3. MATERIALS AND METHODS:  17 
Ethics Statement: The protocol for animal management and euthanasia met the 18 
requirements of The Institutional Animal Care Committee (IACC, protocol number 02-19 
09-08) of the Veterinary College (University of Buenos Aires), the Institutional 20 
Committee for Experimental Animals Use and Management (from INTA, protocol 21 
number 24/2010 for calves and 20/2011 for chickens).  22 
 23 
















Colostrum feeding, experimental groups and passive treatment administration 1 
Fifteen newborn male Holstein calves acquired from the same dairy farm were removed 2 
from their dams at birth prior to suckling and moved into isolation facilities within the first 3 
4 hours of life. The animals were housed in individual isolation rooms under a strict 4 
management protocol as previously described (Parreño et al., 2004). Calves were 5 
randomly assigned to one of the following feeding groups (G): G1= colostrum (C) + milk 6 
supplemented with bovine RVA-specific egg yolk powder with a final ELISA IgY Ab titer 7 
to Indiana RVA strain of 4096 (n=4); G2= C + RVA Ab free milk (n=5) and G3= 8 
colostrum deprived (CD) + RVA Ab free milk (n=6). These last two groups of calves 9 
were considered controls. Colostrum deprived calves are often found in herds where 10 
animals are not artificially assisted and many of the newborns fail to fed before the first 11 
hours of life. Calves in G1 and G2 received 1 L of colostrum pool from RVA non-12 
vaccinated cows (but seropositive to RVA due to natural exposure to the virus in the 13 
field) within the first 6 hours of life (prior to gut closure). This colostrum had a virus 14 
neutralization (VN) Ab titer to Indiana bovine RVA strain (genotype G6P[5]) of 65,536 15 
and an IgG1 ELISA Ab titer of 16,384 and was produced as previously described 16 
(Parreño et al., 2004, 2010; Vega et al., 2011). All animals in G1 and G2 had a 17 
circulating ELISA mean IgG1 Ab titer to Indiana bovine RVA strain of ~1024/4096 in 18 
serum after colostrum intake. Calves in G3 did not receive colostrum but 1 L of RVA Ab 19 
free milk at this time point, remaining seronegative to bovine RVA, as expected. The 20 
milk used in the experiment was commercial sterilized bovine milk for human 21 
consumption (Mastellone Hnos., Argentina). All animals were orally inoculated with 22 
105.85 Focus Forming Units (FFU) of virulent bovine RVA strain G6P[5] (Indiana strain) 23 
















1998). This viral dose was previously confirmed to cause diarrhea and virus shedding in 1 
100% of inoculated CD calves (Parreño et al., 2004). This viral strain is one of the most 2 
prevalent RVA strains circulating in newborn calves in Argentina (Garaicoechea et al., 3 
2006; Badaracco et al., 2012) and worldwide (Midgley et al., 2012; Papp et al., 2013). 4 
Immediately after the onset of diarrhea, only calves assigned to IgY passive treatment 5 
group (G1) received 2 L of the supplemented milk twice a day for 7 days with a final 6 
ELISA IgY Ab titer to bovine RVA (Indiana strain) of 4096. After this time, all calves in 7 
this group were fed milk without supplemental Abs. Calves in G2 and G3 were fed 8 
commercial RVA Ab free milk during the experiment. All the calves were euthanized at 9 
PID 21 to study the primary Ab responses to bovine RVA infection.  10 
 11 
Clinical observations and sample collection: Calves were examined daily for the 12 
development of diarrhea and virus shedding after virulent bovine RVA inoculation. 13 
Rectal temperatures were measured during the experiment and values over 39ºC were 14 
considered as hyperthermia. To estimate the severity of the diarrhea, fecal consistency 15 
was scored blindly by qualified technicians as follows: 0: normal; 1: pasty; 2: semi-liquid; 16 
3: liquid; considering a score equal or greater than 2 as diarrhea (Parreño et al., 2010). 17 
The area under the fecal scores curve (AUC) for each calf was determined and then the 18 
average AUC for diarrhea was calculated for each group. Prior and after virulent bovine 19 
RVA inoculation, fecal samples were collected daily to assess virus shedding. Serum 20 
samples were collected before colostrum feeding (within 4 hours after birth), at bovine 21 
RVA inoculation (approximately 40 hours of birth), and then weekly (PID 7, 14, 21). 22 
Serum Abs to bovine RVA (Indiana G6P[5] strain) were assayed by ELISA and VN 23 
















Peripheral blood lymphocytes (PBL) were sampled at PID 0 and then weekly, to assess 1 
ASC responses by ELISPOT assay. At PID 21, the animals were euthanized and the 2 
number of bovine RVA ASC were quantified by ELISPOT in the following gut-associated 3 
lymphoid tissues (GALT): duodenum, jejunum and ileum lamina propria (LP), jejunum 4 
and ileum Peyer´s patches (PP), jejunum and cecal mesenteric lymph nodes (MLN) and 5 
in systemic lymphoid tissues (spleen and PBL). Large (LIC) and small (SIC) intestinal 6 
contents from all calves were collected at necropsy for bovine RVA specific Ab detection 7 
by ELISA (Parreno, Bejar et al. 2004).  8 
 9 
Virus: Virulent bovine RVA (corresponding to Indiana strain, G6P[5] genotype) inoculum 10 
used for calf experimental infection consisted of the intestinal contents of a CD calf that 11 
was orally inoculated with a fecal suspension containing this RVA strain, as previously 12 
described (Fernandez et al., 1998; Parreño et al., 2004). The cell-culture-adapted 13 
Indiana RVA strain was also propagated in monkey kidney cells (MA-104) for its use in 14 
ELISPOT, ELISA and VN assays (Parreño et al., 2004, 2010).  15 
 16 
Egg yolk powder: Lohmann Brown Classic laying hens were immunized 17 
intramuscularly in the breasts with live attenuated Indiana RVA strain (genotype G6P[5]) 18 
containing 1010 FFU/ml as previously described (Vega et al., 2011).  19 
Collected eggs from immunized hens were grouped weekly and their yolks were diluted 20 
in distilled water at a ratio of 1:3 and stored at -20°C. The RVA IgY Ab titer from each 21 
pool was determined by Indiana RVA ELISA and VN assays and pools with RVA IgY Ab 22 
titers of 16,384 were spray-dried (FlexPump, Galaxie S.A., Argentina) to obtain egg yolk 23 
















ELISA Ab titer to Indiana RVA strain of 1024. A total of 100 gr of egg yolk powder were 1 
diluted in 2 L of RVA Ab free milk to reach an ELISA IgY Ab titer in the supplemented 2 
milk of 4096 (VN titer: 2048) to Indiana RVA strain. The product quality and stability 3 
were evaluated ever a 2 years period. Briefly, samples were kept at room temperature 4 
and relative humidity (RH), at 4°C and room RH, at 30°C and 65% RH or at 40°C and 5 
75% RH in similar trialuminum packages, to generate data on stability from normal or 6 
accelerated conditions, respectively. After 0, 30, 90, 180, 360, 540 and 720 days from 7 
powder production, packages were opened and samples were prepared in RVA Ab free 8 
milk as noted above. The IgY ELISA Ab titer to Indiana RVA strain was determined 9 
immediately. At the same time points, egg yolk powder was sent to a private laboratory 10 
to determine the physicochemical composition and microbiological status of the product. 11 
 12 
Bovine RVA antigen detection: Virus shedding was detected in fecal samples using 13 
an antigen capture ELISA as previously described (Cornaglia et al., 1989). The 14 
genotype and molecular identity of RVA was confirmed by nested RT-PCR followed by 15 
DNA sequence analysis as described elsewhere (Garaicoechea et al., 2006; Badaracco 16 
et al., 2012).  17 
 18 
Cell culture immunofluorescence assay (CCIF): Infectious virus titer was assessed 19 
by a CCIF assay (Fernandez et al., 1998; Parreño et al., 2010). Fluorescent foci were 20 
visualized using FITC-labeled hyperimmune bovine polyclonal antiserum specific to 21 
Indiana bovine RVA strain (genotype G6P[5]) prepared at INTA, and fluorescent foci-22 
forming cells were counted using a fluorescence microscope. Titers were expressed as 23 
















was first determined and then the average AUC for virus shedding was calculated for 1 
the group.  2 
 3 
Bovine isotype-specific Ab ELISA: The IgM, IgA and IgG1 Ab titers to Indiana RVA 4 
strain were determined in colostrum, calf sera, feces, LIC and SIC. Specific IgG1 Abs 5 
were detected by an indirect ELISA while specific IgM and IgA Abs were measured by 6 
capture ELISA using the reagents and protocols previously described (Fernandez et al., 7 
1998; Parreño et al., 2004; Vega et al., 2011). 8 
 9 
RVA specific IgY Ab ELISA: The IgY Ab titers to Indiana RVA strain were determined 10 
in crude egg yolk pools, calf and hen sera, calf feces and supplemented milks by an 11 
indirect ELISA as previously described (Vega et al., 2011).  12 
 13 
Fluorescent focus reduction virus neutralization (FFN) test: Virus neutralizing Ab 14 
titers to Indiana RVA strain in colostrum pools, egg yolk pools supplemented milk and 15 
calf sera were determined by a FFN test as previously described (Parreño et al., 2010; 16 
Vega et al., 2011). The VN titer was expressed as the reciprocal of the highest sample 17 
dilution that resulted in >80% reduction in the number of fluorescent foci (Tô et al., 18 
1998).  19 
 20 
Isolation of mononuclear cells (MNC): Approximately 15 cm of tissue samples of 21 
duodenum, jejunum, and ileum lamina propria were collected. Discrete Peyer´s 22 
patches (PP) (n=4, for each animal) were identified at different points along the 23 
















corresponding to a 10 cm portion of the distal ileum continuous PP was also obtained. 1 
The mesenteric lymph nodes (MLN) corresponding to the jejunum and ileocecal 2 
regions were collected and processed separately. Intestinal tissues were processed as 3 
previously described (Vega et al., 2011). 4 
 5 
ELISPOT assay for bovine RVA-specific ASC: An ELISPOT assay for quantification 6 
of anti-RVA IgM, IgA, IgG1 and IgG2 ASC was conducted to evaluate effector B-cell 7 
responses from all calves at PID 21 in several systemic and gut associated (GALT) 8 
lymphoid tissues, as previously described (Parreño et al., 2004; Vega et al., 2011).  9 
 10 
Statistical analysis: Fisher´s exact test was used to compare proportions of calves with 11 
diarrhea and virus shedding among groups. The Kruskal-Wallis rank sum (non-12 
parametric) test was used to compare days of onset and duration of diarrhea and virus 13 
shedding, cumulative diarrhea scores, AUC, cumulative titers of virus shed and days 14 
with elevated rectal temperature, among groups. VN and isotype-specific Ab titers were 15 
log10-transformed prior to statistical analysis. 16 
Differences in Ab titers among groups were evaluated by general analysis of variance 17 
(ANOVA) followed by DGC (Di Rienzo, Guzmán & Casanoves) multiple comparison test 18 
on repeated measures throughout time. Negative samples at a dilution of 1:4 were 19 
assigned an arbitrary Ab titer of 2 for the calculation of geometric mean titers (GMTs). At 20 
PID 21, the ASC numbers were compared among groups using the Kruskal- Wallis rank 21 
sum test. Statistical significance was assessed at p<0.05 for all comparisons. All the 22 
statistical analyses were conducted using Infostat® 2011p/19/8/2011 (Argentina) 23 


















3.  RESULTS  3 
 4 
Passive treatment with egg yolk powder containing bovine RVA IgY Abs 5 
significantly reduced diarrhea duration and severity compares with colostrum 6 
deprived calves.  7 
 8 
For this experiment, newborn calves assigned to each experimental group were orally 9 
inoculated with virulent bovine RVA (Indiana strain, G6P[5] genotype) at 36 hours of life. 10 
The onset of diarrhea after virus inoculation was statistically similar for all groups of 11 
calves, (G1: 2.0 days; G2: 1.2 days; G3: 2 days). In agreement, bovine RVA infectious 12 
viral particles were detected in feces from all animals by the same day that diarrhea 13 
appeared. Results for diarrhea and virus shedding are detailed in Figure 1. Following 14 
the experimental design, calves assigned to G1 received RVA IgY Ab treatment within 2 15 
hours since the development of diarrhea and for seven consecutive days. Diarrhea in 16 
this group terminated an average of 3.2 days after the beginning of the passive 17 
treatment (range 2 to 5 days). This duration was significantly shorter than the ones 18 
registered for CD calves (10.4 days, G3) while animals fed colostrum followed by RVA 19 
Ab free milk (G2) developed RVA-associated diarrhea of an intermediate duration 20 
(average 7.6 days). Interestingly, virus shedding duration was significantly shorter in 21 
calves in G1 (average 4.5 days) than in animals in G2 (average 11.6 days), while calves 22 
in G3 showed an intermediate duration of 6 days in average. However, the areas under 23 
















experimental groups of calves. Severity of RVA-associated diarrhea, considered as the 1 
average AUC of diarrhea score for each group of calves, was also significantly lower in 2 
RVA IgY Ab treated calves (G1) than in either of the other groups of animals (G2 and 3 
G3). Furthermore, there was a significant reduction in the number of days with RVA-4 
associated hyperthermia for calves in G1 (2.5 days in average) compared with animals 5 
in control groups (G2: 12 days and G3: 11.4 days). It is important to mention that 6 
animals receiving passive RVA-specific IgY Ab treatment (G1) did not show other 7 
clinical signs of bovine RVA infection like anorexia, dehydration or depression (personal 8 
observation, data not shown), while they were evident in all calves in G2 and specially in 9 
G3.  10 
All the calves in G1 cleared the viral infection while they were under passive treatment 11 
with IgY Abs and infectious virus was not detected during the experiment (Figure 1a). As 12 
shown, IgY Abs to Indiana RVA strain from the passive treatment were detected by 13 
ELISA in feces from calves in G1 (Figure 1a). The ELISA IgY Ab titers to RVA varied 14 
daily and could be associated with the viral replication and shedding, especially because 15 
there was an increase in the titers observed once RVA-infection was cleared, around 16 
PID 9-10. Finally, IgY Abs disappeared in one or two days after the end of the passive 17 
treatment (Figure 1a).  18 
 19 
The passive administration of IgY Abs did not suppress the development of 20 
humoral immune responses to RVA.  21 
 22 
Passive or active protection against RVA diarrhea is the most desirable outcome of any 23 
















detected in feces. Moreover, the asymptomatic infection allows development of active 1 
immunity to prevent subsequent natural RVA infections. However, we have also 2 
previously demonstrated that oral passive treatments based on egg yolk cause a strong 3 
positive modulation of the local humoral immune response, and specially the antibody 4 
secreting cell responses in the intestinal mucosa (Vega et al., 2011), so further 5 
characterization of calves immune responses to RVA were conducted.  6 
We studied the local Ab responses to bovine RVA in feces by isotype- specific ELISA. 7 
Results obtained are also depicted in Figure 1 together with virus shedding and diarrhea 8 
duration. For CD calves in G3, bovine RVA-specific IgM and IgA Abs peaked at PID 6 9 
and 7, respectively (Figure 1). A similar pattern was observed in G2 calves (C + RVA Ab 10 
free milk), while IgA Ab peaked at PID 8 and IgM Ab showed low titers from PID 5 to 11 11 
for G1 animals (C + bovine RVA IgY Ab 4096 milk). It is also evident from Figure 1 that 12 
IgG1 Abs to bovine RVA were present around PID 0 in feces from calves receiving 13 
colostrum (G1 and G2) while they were absent in G3 calves. However, from PID 8 on, 14 
animals in G3 (CD + RVA Ab free milk) showed detectable ELISA titers of Indiana RVA 15 
strain specific IgG1 in feces (Figure 1), similarly to the pattern described in serum 16 
(Figure 2). By the end of the experiment, all the calves presented IgG1 as well as IgA 17 
Ab to Indiana RVA strain in feces. Although no other significant differences were 18 
observed between coproAb titers to bovine RVA, calves in G1 showed a trend toward 19 
lower RVA Ab titers than animals in G2 and G3 (Figure 1).  20 
At PID 21, animals were euthanized and contents from large (LIC) and small (SIC) 21 
intestinal sections were collected. Bovine Abs to Indiana RVA strain were also detected 22 
by the same ELISA assay as before (see Figure 1). The IgA and IgG1 Abs were 23 
















RVA Ab free milk) compared to G1 and G2. The IgA Ab titer in SIC from calves in G1 1 
was significantly lower than in calves in G3, with G2 showing intermediate responses. 2 
All the other Ab titers determined were statistically similar among 3 groups of calves. 3 
This was in accordance with the scenario observed in feces at the end of experiment 4 
(Figure 1). 5 
The profile and isotype of bovine Abs to Indiana RVA strain in serum are depicted in 6 
Figure 2. At PID 0 (previous to experimental virulent bovine RVA inoculation), IgG1 Abs 7 
to bovine RVA were present only in animals that received colostrum at birth (G1 and 8 
G2), indicating its transference from the gut to the bloodstream. This was associated 9 
with the presence of VN activity to bovine RVA at this experimental time point for calves 10 
in G1 and G2. The IgG1 Ab titers to Indiana RVA strain remained constant in serum 11 
samples from all the animals in G1 and G2 during the experiment. In these groups of 12 
calves, after virulent bovine RVA inoculation, it was not possible to discriminate if the 13 
detected IgG1 in serum was derived from colostrum intake or of it represented active 14 
production of IgG1 by the neonates (Figure 2). As expected, while no Abs were detected 15 
in serum samples from calves in G3 (CD animals) at PID 0, ELISA Ab titers of IgG1 to 16 
bovine RVA increased progressively from PID 7 to PID 21, and they were statistically 17 
similar between animals in all experimental groups at PID 14 and until the end of the 18 
experiment (PID 21). At PID 21, IgG1 was the main isotype detected in serum, while IgA 19 
and IgM were still present in lower titers in all the experimental groups (Figure 2).  20 
As expected for a primary immune response against RVA, IgM isotype was detected by 21 
ELISA in serum at PID 7 in all calves. At this experimental time point, IgM Ab titers to 22 
Indiana RVA strain were significantly higher in G3 than in G1, while G2 showed 23 
















decreased, reaching statistically similar titers at PID 14 and 21 between groups. On the 1 
other hand, IgA Abs to Indiana RVA strain were also detected from PID 7 on in all 2 
experimental groups of calves, with a peak around PID 14. Calves in G2 had statistically 3 
lower ELISA IgA Ab titers to bovine RVA at PID 14 than animals in G3, while the titers in 4 
G1 were intermediate.  5 
The VN Abs remained constant in G1 throughout the experiment, while in G3 there was 6 
a clear increment from the beginning of the experiment to PID 21. At this experimental 7 
time point, VN titers were statistically similar between all groups. Interestingly, animals 8 
in G2 showed a decrease in IgG1 Ab titers to Indiana RVA strain from PID 7 to 14 9 
(Figure 2). 10 
 11 
Oral treatment with IgY Abs for 7 days was associated with significantly higher 12 
ASC responses in GALT at PID 21.  13 
 14 
At the end of the experiment (PID 21±3), different tissues were collected to determine 15 
the number and isotype of Indiana RVA strain-specific ASC by ELISPOT assay. The 16 
results obtained for “systemic tissues” (blood, spleen, Jejunal MLN and Ileo-cecal MLN) 17 
are depicted in Figure 3 while the ASC responses in GALT are shown in Figure 4. At 18 
PID 21, all the animals had ASC to Indiana RVA strain in the studied tissues. In general, 19 
the numbers of ASC in systemic tissues of calves in G1 (C + RVA IgY Ab) were lower 20 
than in G2 and G3 groups of calves. In particular, the numbers of bovine RVA-specific 21 
IgM and IgG1 ASC responses in the spleens of G1 calves (C + RVA IgY Ab) were 22 
significantly less than the ones in the G2 and G3 animals. In MLN from jejunal and ileo-23 
















RVA strain, where colostrum deprived calves in G3 had higher numbers than animals 1 
from G1 and G2. Interestingly, in G2 calves (C + RVA Ab free), the predominant ASC 2 
isotype detected at PID 21 was IgM followed by IgA in all the systemic tissues studied. 3 
In contrast, in G3 calves (CD + RVA Ab free), most of the bovine RVA-specific ASC 4 
responses were mainly of the IgG1 isotype in these same tissues (Figure 3).  5 
In the case of the GALT responses, most ASC were present in the proximal intestinal 6 
lamina propria (duodenum and jejunum) and, in lower magnitude, in PP, independently 7 
of the treatment (Figure 4). This finding is in agreement with the site of bovine RVA 8 
infection and replication in the small intestine and represents the main GALT effector –9 
duodenum and jejunum- and inductive –ileum- sites, respectively. The ASC responses 10 
to Indiana RVA strain in the duodenum were significantly higher in the IgY- treated 11 
group (G1) than in the control groups (G2 and G3) for IgM, IgA and IgG2 isotypes 12 
(Figure 4). This trend toward higher numbers of bovine RVA ASC was also observed in 13 
other tissues, including Jejunum lamina propria and PP. The ASC responses in G1 were 14 
mainly associated with IgA and IgG2 isotypes, while in G2 and G3 groups IgG1 and IgA 15 
were the most abundant ASC to Indiana RVA strain at PID 21 (Figure 4).  16 
 17 
Development of an oral treatment based on IgY Abs for RVA treatment in calves. 18 
 19 
IgY Abs from chicken egg yolk have been demonstrated to be an effective treatment for 20 
RVA – associated diarrhea. But further experiments are needed to determine if IgY also 21 
could be applied as a commercial product. We studied the stability of egg yolk powder 22 
IgY Ab titers to Indiana RVA strain by ELISA in samples kept in trilaminar aluminum 23 
















depicted in Table 1. The avian IgY Abs reacted with Indiana RVA strain until 2 years 1 
after powder production if the powder was kept at 4°C or even at room temperature. 2 
Under other stability condition, after storing the packaged samples at high temperature 3 
(30°C -65% RH and 40°C – 75% RH), IgY Abs showed a progressive loss of activity 4 
over time (Table 1).  5 
At 180 days (6 months), powder kept at 40°C – 75% RH showed lower ELISA IgY Ab 6 
titers to Indiana RVA strain, that continued decreasing until 720 days. Powder kept at 7 
30°C – 65% RH showed intermediate stabilities, loosing almost all IgY Ab biological 8 
activity by the end of the experiment at 720 days (Table 1).  9 
The physicochemical composition and microbiological status of egg yolk powder were 10 
determined at the packaging stage (0 days from powder production, Table 2) and at the 11 
same time points mentioned above. Regarding the physicochemical composition, it 12 
remained quite similar until the last check-point (720 days from powder production) 13 
when kept at 4°C or even at room temperature. The microbiological status was 14 
acceptable until 360 days in samples kept at room temperature, while it extended until 15 
720 days for sample storage at 4°C. Further assays should be conducted to determine 16 
the safety and commercial viability of a product based on IgY Abs.  17 
 18 
4.  DISCUSSION  19 
 20 
In the present study we evaluated the use of IgY Abs to bovine RVA as a passive oral 21 
therapeutic treatment to control RVA-associated diarrhea in newborn calves. Animals 22 
were experimentally inoculated with bovine Indiana RVA strain (genotype G6P[5]), the 23 
















2012; Midgley et al., 2012; Papp et al., 2013). As control groups, colostrum- deprived 1 
animals and calves receiving colostrum, but not treated with any RVA-specific passive 2 
treatment were included. Although normally newborn calves would receive at least one 3 
liter of colostrum from their mothers, many of them fail to stand in the first hours of life 4 
and nurse soon enough before gut closure. These calves are frequently found in dairy 5 
herds from Argentina and their survival is compromised by the lack of passively 6 
transferred maternal immune factors and antibodies (Tripathi and Vashishtha, 2006; 7 
Osaka et al., 2014). The results obtained demonstrate that daily oral administration of 8 
egg yolk powder enriched in IgY Ab to bovine RVA at a final ELISA Ab titer of 4096 (VN 9 
titer: 2048, to Indiana RVA strain, genotype G6P[5]) significantly reduced the number of 10 
days with diarrhea and hyperthermia as well as the severity of the illness when 11 
compared with colostrum deprived calves that did not receive any virus-specific 12 
treatment.  13 
Regarding virus shedding, calves treated with IgY Abs to bovine RVA cleared virus 14 
infection before the end of the passive treatment and significantly earlier than control 15 
animals receiving colostrum but without IgY Ab treatment (G2). Also, heterologous IgY 16 
Abs were detected by ELISA in feces, suggesting that they were not completely 17 
degraded in the intestinal tract. The resistance of IgY Abs to the calf´s gut environment 18 
was also previously observed by our group in the administration of fluid crude egg yolk 19 
as a passive prophylactic treatment to prevent RVA-associated diarrhea in newborn 20 
calves (Vega et al., 2011).  21 
Another important novel feature observed in this study is the induction of a stronger 22 
RVA-specific ASC response in calves receiving milk supplemented with chicken egg 23 
















Ab free milk. This feature was previously observed in calves fed milk supplemented with 1 
crude egg yolk administered as a preventive strategy for a longer period of time (Vega 2 
et al., 2011). These results together demonstrate that this immunomodulatory activity is 3 
local, affecting only GALT ASC responses. In the current experiment, calves were fed 4 
egg yolk powder for only 7 days, half of the time compared to previous prophylactic 5 
experiments. Yet, the modulatory effect of egg yolk supplementation was clearly 6 
maintained. These high numbers of bovine RVA-specific ASC detected in the GALT of 7 
egg yolk treated animals represent a powerful active immune strategy to control bovine 8 
RVA diarrhea as well as potentially other enteric infections. These results are in 9 
agreement with the presence of immunomodulatory molecules in the egg yolk, that 10 
promote B cell clonal expansion and IgA switching related to anti-inflammatory 11 
responses to dietary antigens (Nelson et al., 2007). It has been previously demonstrated 12 
that this immunomodulatory effect of egg yolk is not related to IgY Abs itself, as calves 13 
treated with semi-purified IgY Abs for 14 days as well as gnotobiotic pigs fed milk 14 
supplemented with semi-purified IgY Abs for 9 days did not develop statistically higher 15 
ASC responses in GALT than control groups (Vega et al., 2012). However, it seems like 16 
IgY Ab treatment caused a partial suppression of active systemic Ab responses to 17 
bovine RVA. This could be associated with less severe diarrhea in treated calves, as 18 
systemic Ab responses to bovine RVA seem to be higher in colostrum deprived calves, 19 
while G2 calves showed intermediate responses.  20 
It has been reported that IgY Abs against bovine RVA can be used to prevent virus-21 
associated diarrhea in newborn calves (Vega et al., 2011). In this work we focus on the 22 
treatment of clinical signs of bovine RVA infection once they appear, as many farmers 23 
















passive treatment from 14 to 7 days when compared to previous prophylactic 1 
experiments by our group (Parreño et al., 2010; Vega et al., 2011). However, even with 2 
only 7 days of twice daily continuous treatment, IgY Abs were a strong and versatile 3 
immune strategy against bovine RVA-associated diarrhea. Another important feature is 4 
the fact that the passive treatment administered to calves in this experiment consisted 5 
mainly of egg yolk powder, which can be easily manipulated and kept at room 6 
temperature for long periods of time (even until 12-16 months). These properties 7 
emphasize the advantages of egg yolk as a source of specific antibodies. Avian Ab 8 
represent both a reduction and refinement in animal use (Karlsson et al., 2004). When 9 
considering Ab production for passive immunotherapy applications, chickens present a 10 
much more economical source of large quantities of specific Ab being also less invasive 11 
as it only requires daily collection of eggs (Mine and Kovacs-Nolan, 2002; Karlsson et 12 
al., 2004; Schade et al., 2005; Kovacs-Nolan and Mine, 2012). It would be critical to 13 
develop an egg yolk powder enriched in IgY Abs directed to several enteropathogens 14 
involved in neonatal calf diarrhea. This will represent a polyvalent product to be used as 15 
a preventive as well as a therapeutic strategy to control calf scours in dairy farms. Being 16 
an Ab-based therapy consisting of polyclonal heterologous Abs to bovine RVA, this 17 
passive oral treatment will help to control neonatal calf diarrhea. Importantly, this 18 
approach will help overcome the problem of microbial resistance to antibiotics, which 19 
are used indiscriminately to treat calf diarrhea, offering an innovative, ecological and 20 
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Figure Legends: 1 
Figure 1- Virus shedding, diarrhea duration and coproAbs titers in feces of the 2 
experimental groups of calves. Calves in G1 were fed two liters of commercial bovine 3 
milk supplemented with 100 g of egg yolk powder containing Indiana RVA strain-specific 4 
IgY Abs, twice a day for seven days from diarrhea onset. Calves in G2 and G3 were fed 5 
RVA Ab free milk without any supplementation. Continuous lines represent the average 6 
ELISA Ab titer of isotype-specific bovine coproAbs to bovine Indiana RVA strain 7 
detected in feces. Dashed line in G1 represents the average ELISA IgY Ab titer to 8 
Indiana RVA strain. Columns represent average daily profile of virus shedding for 9 
experimental calves expressed as FFU/ml. Horizontal bar indicates mean diarrhea 10 
duration. Tables included in each graph indicate diarrhea duration defined as the 11 
number of days with fecal score ≥2. Feces consistency was scored daily (0=normal; 12 
1=pasty; 2=semi-liquid; 3=liquid).  1 Means in the same column with different superscript 13 
upper case letters differ significantly (Kruskal-Wallis rank sum test; p<0.05). 2 14 
Determined by ELISA and CCIF. Number of days with bovine RVA-associated 15 
hyperthermia was considered as days with body temperature >39ºC. C= colostrum / CD 16 
= colostrum deprived. AUC: area under the diarrhea/virus shedding curve. PID: post 17 
inoculation day. VS: virus shedding. LIC: large intestinal contents. SIC: small intestinal 18 
contents.  19 
  20 
Figure 2- Geometric mean isotype-specific and neutralizing Ab titers (GMTs) to Indiana 21 
RVA (G6P[5] strain) in serum collected weekly (lines). a) G1: calves fed with colostrum 22 
(C) followed by bovine RVA egg yolk supplemented milk with a final Indiana RVA IgY Ab 23 
















C followed by non-supplemented RVA Ab free milk; c) G3: colostrum deprived calves 1 
receiving RVA Ab free milk. All calves were orally inoculated with virulent Indiana RVA 2 
strain at 0 PID. Statistical analysis of the Ab titers in serum was performed by ANOVA 3 
followed by DGC multiple comparison test through time, p < 0.05. The “–“ indicates no 4 
significant differences between groups. 5 
 6 
Figure 3- Mean numbers of bovine RVA ASC per 5 × 105/MNC obtained from systemic 7 
lymphoid tissues (PBL, spleen and MLN draining the small and large Intestine), at 21 8 
PID. G1: calves fed with colostrum (C) followed by bovine RVA egg yolk supplemented 9 
milk with a final bovine RVA IgY Ab titer of 4096 for 7 consecutive days once diarrhea 10 
appearance; G2: calves receiving C followed by non-supplemented RVA Ab free milk; 11 
G3: colostrum deprived calves receiving RVA Ab free milk. All calves were orally 12 
inoculated with virulent Indiana RVA strain at 0 PID. For each tissue, when comparing 13 
mean ASC numbers of the same isotype, among treatment groups: different letter 14 
indicate a significant difference (Kruskal–Wallis rank sum test, p < 0.05). n = number of 15 
calves in each group. Error bars indicate SD. The “–“ indicates no significant differences 16 
between groups. 17 
 18 
Figure 4- Mean numbers of bovine RVA ASC per 5 × 105/MNC obtained from GALT at 19 
21 PID. G1: calves fed with colostrum (C) followed by milk supplemented with bovine 20 
RVA egg yolk with a final Indiana RVA IgY Ab titer of 4096 for 7 consecutive days after 21 
diarrhea appearance; G2: calves receiving C followed by non-supplemented RVA Ab 22 
free milk; G3: colostrum deprived calves receiving RVA Ab free milk. All calves were 23 
















tissue, when comparing mean ASC numbers of the same isotype, among treatment 1 
groups: different letter indicate a significant difference (Kruskal–Wallis rank sum test, p 2 
< 0.05). n = number of calves in each group. Error bars indicate SD. The “–“ indicates 3 
no significant differences between groups. 4 
 5 
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Table 1- Stability of egg yolk powder IgY Ab titer to bovine RVA (Indiana G6P[5] strain) 1 
determined by ELISA in 10 mg/ml solution from samples kept at different storage 2 
conditions.  3 
 4 
After 0, 30, 90, 180, 360, 540 and 720 days from powder production, packages were 5 
opened and samples were prepared in milk as described in Materials and Methods. The 6 
IgY ELISA Ab titer to bovine RVA (Indiana G6P[5] strain) was determined immediately 7 
by ELISA assay. RH: relative humidity. 8 
Table 2- Physicochemical composition and microbiological status of egg yolk powder at 9 
packaging (0 days from powder production). 10 
 11 
Physicochemical composition Microbiological status 
% Humidity % Fat % Protein Total Coliforms (CFU/g) Salmonella sp. 
2.97 39.63 48.31 <10 
Absent  
(in 25 g)  
Egg yolk powder samples were specially taken at the packaging stage and sent to a 12 
private laboratory to determine its physicochemical composition and microbiological 13 
status. CFU/g: colony-forming units per gram. 14 
  15 
Storage Conditions Days from egg yolk powder production 
 0 30 90 180 360 540 720 
4°C and room RH 1024 1024 1024 1024 1024 1024 1024 
Room Temperature and RH 1024 1024 1024 1024 1024 1024 1024 
30ºC – 65% RH 1024 1024 1024 256 256 64 4 
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- Neonatal calf diarrhea is a critical problem and passive therapy with IgY Abs is a way to control it.  4 
- There are no solid studies using Rotavirus specific IgY Abs once calves suffer diarrhea.  5 
- We provide here scientific information regarding the effects of IgY-based products. 6 
- This information is critical considering that IgY Abs are being sold in several countries.  7 
- We prove the therapeutic value of IgY –based treatment and the industrialization of this product. 8 
 9 
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